The activation of the neurohormonal and sympathetic systems has been demonstrated in heart failure, and blocking these pathways using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenergic blockers is useful to reduce the progression of heart failure and improve clinical outcomes , , 29-31. The gene discussed is ACE; the disease is heart failure.